FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311573880> ?p ?o ?g. }

• W4311573880 abstract "Multiple myeloma is an incurable haematological malignancy that is associated with a high probability of relapse. The survival of relapsed patients has been greatly improved by the development of novel drugs such as lenalidomide and bortezomib. We assessed the cost-effectiveness of these drugs as second-line treatment for relapsed/refractory multiple myeloma (RRMM) patients in the South African public health care system.We modelled 3 treatment strategies for second-line RRMM treatment: dexamethasone (standard of care), bortezomib (BORT) and lenalidomide plus dexamethasone (LEN/DEX) from the South African public health perspective. For each strategy we modelled a hypothetical cohort of relapsed/refractory multiple myeloma patients using a three-state Markov model over a 15-year time horizon. Efficacy and utilization data were obtained from the MM009/010 and APEX trials and external studies. Price and cost data were from local sources and presented in 2021 South African Rands. Outcomes were reported in quality adjusted life years (QALYs). Incremental cost effectiveness ratios (ICERs) were calculated for BORT and LEN/DEX and compared to a local cost-effectiveness threshold of R38 500 per DALY averted using the assumption that 1 DALY averted is equal to 1 QALY gained. A budget impact analysis was conducted to evaluate the financial impact of the introduction of BORT and LEN/DEX, respectively. Deterministic sensitivity analysis was undertaken to account for parameter uncertainties.The modelled total costs of DEX, BORT and LEN/DEX were estimated to be R8 312, R234 996 and R1 135 323, respectively. DEX treatment provided 1.14 QALYs while BORT and LEN/DEX treatments provided 1.49 and 2.22 QALYs, respectively. The ICER of BORT versus DEX was R654 649 and that of LEN/DEX versus BORT was R1 225 542. Both BORT and LEN/DEX treatments were not cost-effective relative to a cost-effectiveness threshold of R38 500 per DALY averted. Both BORT and LEN/DEX significantly increase the 1 year budget-cost of RRMM treatment.Both BORT and LEN/DEX treatments are unlikely to be cost-effective strategies for second-line treatment of RRMM in South Africa. The results indicate that the drug prices of lenalidomide and bortezomib are key drivers of value for money. Price reductions could potentially make BORT more cost-effective." @default.
• W4311573880 created "2022-12-27" @default.
• W4311573880 creator A5001797461 @default.
• W4311573880 creator A5054804786 @default.
• W4311573880 creator A5055442587 @default.
• W4311573880 date "2022-12-12" @default.
• W4311573880 modified "2023-10-06" @default.
• W4311573880 title "Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective" @default.
• W4311573880 cites W1536921365 @default.
• W4311573880 cites W1963559518 @default.
• W4311573880 cites W1978393082 @default.
• W4311573880 cites W1989778394 @default.
• W4311573880 cites W2000069677 @default.
• W4311573880 cites W2015562245 @default.
• W4311573880 cites W2020368872 @default.
• W4311573880 cites W2044415411 @default.
• W4311573880 cites W2060496777 @default.
• W4311573880 cites W2077421070 @default.
• W4311573880 cites W2111650326 @default.
• W4311573880 cites W2133104890 @default.
• W4311573880 cites W2145102719 @default.
• W4311573880 cites W2146803994 @default.
• W4311573880 cites W2150570212 @default.
• W4311573880 cites W2151684406 @default.
• W4311573880 cites W2286756681 @default.
• W4311573880 cites W2322208802 @default.
• W4311573880 cites W2346829286 @default.
• W4311573880 cites W2557867537 @default.
• W4311573880 cites W2567188480 @default.
• W4311573880 cites W2800177702 @default.
• W4311573880 cites W2883988942 @default.
• W4311573880 cites W2888120887 @default.
• W4311573880 cites W2901680878 @default.
• W4311573880 cites W2912830333 @default.
• W4311573880 cites W2913976792 @default.
• W4311573880 cites W2948684401 @default.
• W4311573880 cites W3010313261 @default.
• W4311573880 cites W3042314403 @default.
• W4311573880 cites W3117957681 @default.
• W4311573880 doi "https://doi.org/10.1186/s12962-022-00399-4" @default.
• W4311573880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36510230" @default.
• W4311573880 hasPublicationYear "2022" @default.
• W4311573880 type Work @default.
• W4311573880 citedByCount "0" @default.
• W4311573880 crossrefType "journal-article" @default.
• W4311573880 hasAuthorship W4311573880A5001797461 @default.
• W4311573880 hasAuthorship W4311573880A5054804786 @default.
• W4311573880 hasAuthorship W4311573880A5055442587 @default.
• W4311573880 hasBestOaLocation W43115738801 @default.
• W4311573880 hasConcept C112930515 @default.
• W4311573880 hasConcept C126322002 @default.
• W4311573880 hasConcept C142724271 @default.
• W4311573880 hasConcept C143998085 @default.
• W4311573880 hasConcept C2776063141 @default.
• W4311573880 hasConcept C2776125615 @default.
• W4311573880 hasConcept C2776364478 @default.
• W4311573880 hasConcept C2777478702 @default.
• W4311573880 hasConcept C2780401358 @default.
• W4311573880 hasConcept C3019080777 @default.
• W4311573880 hasConcept C71924100 @default.
• W4311573880 hasConceptScore W4311573880C112930515 @default.
• W4311573880 hasConceptScore W4311573880C126322002 @default.
• W4311573880 hasConceptScore W4311573880C142724271 @default.
• W4311573880 hasConceptScore W4311573880C143998085 @default.
• W4311573880 hasConceptScore W4311573880C2776063141 @default.
• W4311573880 hasConceptScore W4311573880C2776125615 @default.
• W4311573880 hasConceptScore W4311573880C2776364478 @default.
• W4311573880 hasConceptScore W4311573880C2777478702 @default.
• W4311573880 hasConceptScore W4311573880C2780401358 @default.
• W4311573880 hasConceptScore W4311573880C3019080777 @default.
• W4311573880 hasConceptScore W4311573880C71924100 @default.
• W4311573880 hasIssue "1" @default.
• W4311573880 hasLocation W43115738801 @default.
• W4311573880 hasLocation W43115738802 @default.
• W4311573880 hasLocation W43115738803 @default.
• W4311573880 hasLocation W43115738804 @default.
• W4311573880 hasOpenAccess W4311573880 @default.
• W4311573880 hasPrimaryLocation W43115738801 @default.
• W4311573880 hasRelatedWork W14748329 @default.
• W4311573880 hasRelatedWork W1699374300 @default.
• W4311573880 hasRelatedWork W1988784378 @default.
• W4311573880 hasRelatedWork W1996748901 @default.
• W4311573880 hasRelatedWork W2192430028 @default.
• W4311573880 hasRelatedWork W2330049167 @default.
• W4311573880 hasRelatedWork W2604776612 @default.
• W4311573880 hasRelatedWork W3134875278 @default.
• W4311573880 hasRelatedWork W3217566318 @default.
• W4311573880 hasRelatedWork W2309095625 @default.
• W4311573880 hasVolume "20" @default.
• W4311573880 isParatext "false" @default.
• W4311573880 isRetracted "false" @default.
• W4311573880 workType "article" @default.